NASDAQ$CVRX
CVRx Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
CVRx's first quarter performance demonstrated solid execution with significant revenue growth and progress in the U.S. heart failure business.
CVRx reported a strong first quarter in 2023, with revenue reaching $8.0 million, a 96% increase compared to the same period in 2022. The company saw substantial growth in the U.S. heart failure business, driven by increased adoption of Barostim. Gross profit and gross margin also improved significantly.
- Revenue increased by 96% to $8.0 million compared to Q1 2022.
- U.S. revenue grew by 127% to $6.9 million, driven by the heart failure business.
- Gross profit increased by 113% to $6.7 million, with gross margin improving to 83%.
- The number of active implanting centers increased to 122 as of March 31, 2023.
Headline financials
Revenue & EPS history
CVRx · Revenue · Quarterly
$7.98M
Forward guidance
For the second quarter of 2023, the Company expects to report total revenue between $8.2 million and $8.8 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2023
-0.9%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+36.7%
Q3 2024
Best reaction
-39.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.7% | -13.3% | -29.2% | |
| Q4 2025 | -13.0% | -14.8% | +32.3% | |
| Q3 2025 | +0.8% | -3.4% | -8.5% | |
| Q1 2025 | -39.0% | -32.0% | -15.7% | |
| Q4 2024 | -7.2% | -8.4% | -28.8% | |
| Q3 2024 | +36.7% | +30.2% | +48.8% | |
| Q2 2024 | -17.5% | -14.4% | +3.3% | |
| Q1 2024 | -33.8% | -39.7% | -55.0% | |
| Q4 2023 | -1.4% | -6.1% | -19.6% | |
| Q3 2023 | -1.2% | +0.5% | +50.4% | |
| Q2 2023 | +6.2% | +5.7% | +2.3% | |
| Q1 2023 | +24.0% | +34.2% | +41.1% | |
| Q4 2022 | +3.1% | +5.9% | -24.2% | |
| Q3 2022 | +2.7% | +21.4% | +43.1% | |
| Q2 2022 | +22.1% | +24.6% | +4.6% | |
| Q1 2021 | -3.4% | -12.0% | -6.3% | |
| Q1 2022 | +12.6% | +28.5% | +14.0% | |
| Q4 2021 | +0.9% | +0.0% | -21.2% | |
| Q3 2021 | +4.8% | +4.1% | -36.5% | |
| Q2 2020 | -4.7% | -13.0% | -13.0% | |
| Q2 2021 | -5.6% | -7.5% | -15.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro